- Home
- /
- Brands listing
- /
- Alimentary Tract And Metabolism
- /
- Reimbursed
List of reimbursed drugs, is an important part of Service Packages covering the Fund of Compulsory Health Care Insurances for the population. The list of reimbursable drugs aims at improving the quality of service for all patients, particularly for people in need. In this regard, through the new list of drugs, FCHC aims at increasing the attention toward categories such as retirees and patients suffering from serious illnesses.
In compiling the list of drugs there are some scientific criteria which have been taken into consideration, by giving priority to drugs used for severe diseases; diseases of high risk for life; diseases that cause disability; diseases that risk of being spread into the society; diseases that cause much suffering as well as chronic illnesses requiring prolonged treatment.
Alimentary Tract And Metabolism - Reimbursed
Oral drops solution – (10.000 UI + 10.000 UI) / ml
Solution for injection - (0.1%) 1 mg/1 ml
Tablets - 5 mg
Tablets - 500 mg
Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).
Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.
In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.
Tablets - 850 mg
Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).
Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.
In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.
